My SEC Response. Didn’t answer my question. Here it is.
Dear Michael Bliss:
Dear Michael Bliss:
Thank you for contacting the U.S. Securities and Exchange Commission (SEC).
We appreciate you taking the time to inform us of your concerns regarding Generex Biotechnology Corp (OTC: GNBT) and Nugenerex Immuno-Oncology Inc. (OTC: NUGX). The Office of Investor Education and Advocacy (OIEA) processes many complaints received from individual investors and others. We keep records of the correspondence we receive in a searchable database that SEC staff may make use of in inspections, examinations, and investigations. In addition, some correspondence received by OIEA is referred directly to other SEC offices and divisions for their review. If they have any questions or wish to respond directly to your comments, they will contact you.
NUGX and GNBT trade on the OTC Markets. You can find additional information on the OTC Markets and the attendant risk of the companies trading there by visiting the following SEC websites: http://www.sec.gov/answers/pink.htm and
https://www.investor.gov/additional-resources...ocap-fraud.
Based upon information provided to OTC Markets, NUGX and GNBT are incorporated in the State of Delaware. Thus, you may wish to contact Delaware securities regulators for any information they can provide. Contact information is as follows:
Carvel State Office Building
820 North French Street, 5th Fl.
Wilmington, DE 19801
(302) 577-8424
(302) 577-6987 (Fax)
https://attorneygeneral.delaware.gov/fraud/ipu/
The SEC conducts its investigations on a confidential and nonpublic basis and neither confirms nor denies the existence of an investigation unless the SEC brings charges against someone involved. We do this to protect the integrity and effectiveness of our investigative process and to preserve the privacy of the individuals and entities involved. As a result, we will be unable to confirm whether an investigation exists or provide you with any updates on the status of your complaint or of any pending SEC investigation. Information on our policy is enclosed. You may wish to check our website, www.sec.gov, for information about pending SEC civil actions, administrative cases, and other matters.
If you have any other questions, please contact me by reply email (help@sec.gov).
Sincerely,
Amy Rosenthal
Investor Assistance Specialist
Office of Investor Education and Advocacy
U.S. Securities and Exchange Commission
(800) 732-0330
www.sec.gov
www.investor.gov
www.twitter.com/SEC_Investor_Ed
Dear Michael Bliss:
Dear Michael Bliss:
Thank you for contacting the U.S. Securities and Exchange Commission (SEC).
We appreciate you taking the time to inform us of your concerns regarding Generex Biotechnology Corp (OTC: GNBT) and Nugenerex Immuno-Oncology Inc. (OTC: NUGX). The Office of Investor Education and Advocacy (OIEA) processes many complaints received from individual investors and others. We keep records of the correspondence we receive in a searchable database that SEC staff may make use of in inspections, examinations, and investigations. In addition, some correspondence received by OIEA is referred directly to other SEC offices and divisions for their review. If they have any questions or wish to respond directly to your comments, they will contact you.
NUGX and GNBT trade on the OTC Markets. You can find additional information on the OTC Markets and the attendant risk of the companies trading there by visiting the following SEC websites: http://www.sec.gov/answers/pink.htm and
https://www.investor.gov/additional-resources...ocap-fraud.
Based upon information provided to OTC Markets, NUGX and GNBT are incorporated in the State of Delaware. Thus, you may wish to contact Delaware securities regulators for any information they can provide. Contact information is as follows:
Carvel State Office Building
820 North French Street, 5th Fl.
Wilmington, DE 19801
(302) 577-8424
(302) 577-6987 (Fax)
https://attorneygeneral.delaware.gov/fraud/ipu/
The SEC conducts its investigations on a confidential and nonpublic basis and neither confirms nor denies the existence of an investigation unless the SEC brings charges against someone involved. We do this to protect the integrity and effectiveness of our investigative process and to preserve the privacy of the individuals and entities involved. As a result, we will be unable to confirm whether an investigation exists or provide you with any updates on the status of your complaint or of any pending SEC investigation. Information on our policy is enclosed. You may wish to check our website, www.sec.gov, for information about pending SEC civil actions, administrative cases, and other matters.
If you have any other questions, please contact me by reply email (help@sec.gov).
Sincerely,
Amy Rosenthal
Investor Assistance Specialist
Office of Investor Education and Advocacy
U.S. Securities and Exchange Commission
(800) 732-0330
www.sec.gov
www.investor.gov
www.twitter.com/SEC_Investor_Ed
1
